New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced that it closed its Series A Financing Round at $2.5 million. The financing was over-subscribed due to investor demand. New View Surgical will deploy the financing to complete the development of its VisionPort™ System, expand the company’s intellectual property portfolio and submit a 510(k) U.S. Food and Drug Administration (FDA) filing.
"We are very pleased to have closed our Series A financing and are encouraged by the confidence shown by our investors, including individual members from New York Angels, Mid-Atlantic Bio-Angels, Keiretsu Forum and Ariel Southeast Angel Partners, among others," said Bryce Klontz, President & Chief Executive Officer at New View Surgical. “Most importantly, we’re leveraging this capital to bring a surgical technology to market that supports our overall mission to decrease cost, improve surgical imaging and increase access to minimally invasive surgical procedures for patients around the world.”
“I am very excited about the efficiency and progress made by the team at New View Surgical,” said David Earle, MD, FACS, Director of the New England Hernia Center, Associate Professor of Surgery at Tufts University School of Medicine, and Scientific Advisory Board member of New View Surgical. “Not only will this technology allow more patients to access minimally invasive surgical techniques, it will make many high-volume cases easier for surgeons to perform.”
New View Surgical’s initial device, the VisionPort™ System, is a novel surgical imaging and access system for minimally invasive surgery that aims to simplify laparoscopic procedures across all specialties by reducing the need for a separate camera port and camera holder and allowing multiple simultaneous views of the operative field. In emerging markets, the VisionPort™ System will greatly reduce the capital-intensive equipment currently required to perform minimally invasive surgery, and thus, allow access to the latest in surgical techniques where it is currently unavailable. Dr. Earle stated, “the VisionPort™ System allows the surgeon to control the scope and keeps the tip of the instruments within the field of view at all times. This has significant potential to make the operation easier for the surgeon and may reduce risk to the patient as well. Furthermore, having multiple simultaneous views of the operative field allows for different viewing angles that were previously possible only by removing the scope and moving it to another port. Moving the scope frequently smudges the scope, creates condensation on the lens, causes frustration and wastes time. The elimination of the camera port and an assistant to hold the scope means surgeons and hospitals can be more efficient by accommodating more procedures, which is good for the surgeon, the facility, and most importantly, the patient.”
About New View Surgical, Inc. New View Surgical is an emerging medical device company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging and access system for minimally invasive surgery. The company is led by an experienced team of medical device innovators and commercial experts who have come together to design and commercialize impactful solutions that meet a variety of unmet market needs. The company’s proprietary VisionPort™ system combines multiple imaging and access devices into just one simple, easy-to-use device that is disposable and is expected to bring a variety of clinical and economic advantages to minimally invasive surgery operating rooms around the world. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.
NEW YORK, Nov. 10, 2017 -- Mid Atlantic Bio Angels (MABA) announces today that it has made an investment in Boston-based New View Surgical., which has developed a proprietary surgical imaging system for laproscopic surgery. This is the eighth investment made by MABA since its founding.
“Laproscopic and minimally invasive surgeries have become the norm, and it is important that physicians have the most updated technology to both improve outcomes through enhanced control, while hospitals are given the opportunity to continue to minimize costs,” said Yaniv Sneor, a MABA co-founder and president of Blue Cactus Consulting. “We have been impressed with New View Surgical’s technology and management, and believe they offer solutions that will help bring laproscopic surgeries to the next level.”
New View Surgical is an early-stage surgical visualization company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging system for minimally invasive surgery. The company’s proprietary VisionPort™ system combines four instruments into one and is being developed as a disposable device. It enters as a trocar, functions as a laparoscope and deploys as a camera and an instrument channel. The key advantage of VisionPort over current visualization systems is that, for the first time, it gives the primary surgeon total control of both the instruments and visualization. The system provides a full, straight-on view of the tissue and instrument tips at all times, limiting accidental injury to adjacent organs as well as lowering the surgeon’s skill threshold and ergonomic stress. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.
“The New View Surgical team is very pleased to have multiple MABA members participate in our Series A round. The investments from MABA support the further development of our VisionPort™ System and our team’s mission to improve the safety, efficiency and cost profile of today’s surgical visualization equipment,” said Bryce Klontz, president and CEO of New View Surgical. “The memberships’ overall focus on the life-sciences also offers us a strong group of sophisticated investors with whom our team can network throughout the critical months ahead.”
About Mid Atlantic Bio Angels Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
BOSTON, May 19, 2016 – Today New View Surgical, Inc. announced it will join MassChallenge Boston, the most startup-friendly accelerator on the planet. One of 128 startups participating, New View Surgical, Inc. will benefit from mentorship, office space, and a vast network of experienced entrepreneurs, corporate partners, and investors. In November, all MassChallenge Boston startups will compete for $1.5M total in cash awards with no equity taken.
“The team at New View Surgical, Inc. is extremely proud of being selected as a Finalist from over 1,700 applicants for the MassChallenge 2016 Accelerator. We fully expect that the extensive network of entrepreneurs, business partners and investors associated with MassChallenge will help propel New View Surgical toward achieving our goal of commercializing the VisionPort™, our novel, game-changing surgical imaging technology that aims to redefine and simplify laparoscopic surgery”, commented Bryce Klontz, New View Surgical’s President and CEO.
“We received consistent feedback from our judges about the quality of applicants this year, and I'm confident we’ll have an incredibly high-caliber class of entrepreneurs joining us in Boston," added MassChallenge Boston Managing Director Scott Bailey. "These entrepreneurs will be challenged throughout the program to impact communities and provide disruptive solutions across a wide range of industries. Be on the lookout for them this summer!”
This year’s MassChallenge Boston class was selected from more than 1,700 applicants across a diverse range of industries and geographies, including 65 countries and 37 states. The accelerator program will culminate on November 2, 2016, at the MassChallenge Boston Awards Ceremony, where entrepreneurs will pitch their startups with the chance to win a share of $1.5 million in zero-equity awards.
New View Surgical, Inc., an early-stage surgical imaging company in Boston, Massachusetts, announced today that it has been selected as a Presenting Company at the upcoming 2016 Emerging Medical Technology Summit to be held in San Francisco, November 9-11, 2016. The prestigious EMT Summit is co-hosted by Life Science Intelligence and The MedTech Strategist and will feature presentations by CEOs of 70 hand-picked early-stage medical device companies from around the world raising capital and/or seeking quality strategic partners.
New View Surgical, Inc., an early-stage surgical imaging company in Boston, Massachusetts, announced today that it has named Bryce Klontz as President &CEO, effective immediately. Mr. Klontz is an accomplished global sales and marketing executive, having built and led commercial teams in the US, Europe and Asia. Most recently, Mr. Klontz was the Vice President of Commercial Strategy, Emerging Markets at Covidien, PLC where he led efforts to build commercial capabilities within the $1.5B+ Asia, Latin America, Emerging Europe, Middle East and Africa geographies. Mr. Klontz spent 14 years at Covidien in various leadership roles including Marketing Director in both the US and Europe, as well as 3 years as Vice President, Surgical Devices Business Unit, in Asia. Mr. Klontz also served as the global post-M&A integration lead for two of Covidien's most impactful acquisitions. Earlier in his career, Mr. Klontz played a pivotal role in the global launch of The CO2 Heart Laser System. Mr. Klontz received his MBA in marketing and finance from Carroll School of Management at Boston College and a Bachelor's degree from Northwestern University.
New View Surgical, Inc., an early-stage surgical imaging company in Boston, Massachusetts, announced today that the U.S. Patent and Trademark Office has issued a patent for the design behind the company’s entry device, the VisionPort™. The recently-issued patent (U.S. Patent Number 8,834,358 B2) is an extension of the Company’s initial patent (US Patent# 8,439,830 B2) issued in May 14, 2014 and was issued for a cannula-based system with an integrated camera and illumination. With this exclusive technology, visualization of the operative field is under the direct control of the primary surgeon through each one of his or her access ports, improving surgical outcomes and procedural efficiency.
2017 Angel Capital Association Summit and 5th Annual Innovation Showcase
April 26-28, 2017, San Francisco Marriott Marquis
780 Mission Street, San Francisco, CA 94103
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)
March 22-25, 2017, Houston, TX
Angel Capital Expo
March 16, 2017, Microsoft Building 33, Redmond, Washington
Presenter: Keiretsu Forum Angel Capital Expo
January 10, 2017, Marine’s Memorial Club & Hotel
609 Sutter Street, San Francisco, CA 94102
August 31 – September 3, 2016, Westin Copley Place Hotel, Boston, MA
Minimally Invasive Surgery Week
October 28, 2016, Westin, Waltham, Massachusetts
Presenter. MassMEDIC MedTech Showcase
November 9-11, 2016, Hotel Sofitel San Francisco, CA
Presenter. Emerging Medical Technologies Summit
March 16-19, 2016, Boston, MA
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES)